This inventor holds 1 USPTO granted patent. Top assignee: Abbott Laboratories Corporation. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: Innovations by Jack Zheng in Pulmonary Delivery Systems.
Introduction
Jack Zheng is an accomplished inventor based in Lake Bluff, Illinois. He has made significant contributions to the field of pulmonary delivery systems, particularly through his innovative formulations for administering dopamine agonists. His work aims to enhance the effectiveness of treatments for patients requiring such medications.
Latest Patents
Jack Zheng holds a patent for "Formulations for pulmonary delivery of dopamine agonists." This invention relates to methods and formulations designed to administer a dopamine agonist directly to the airways of a patient. The preferred dopamine agonist in his patent is (5aR-trans)-4,5,6,7,11b-hexahydro-2-propylbenzo[f]thieno[2,3-c]quinoline-9,10-diol, diacetate (ester) hydrochloride. The delivery method encompasses specific aerosol and liquid formulations that ensure effective delivery of dopamine agonists to the receptor sites in the airways.
Career Highlights
Jack Zheng is currently employed at Abbott Laboratories Corporation, a leading global healthcare company. His role involves research and development focused on innovative drug delivery systems. His expertise in this area has led to advancements that benefit patients requiring pulmonary treatments.
Collaborations
Jack has collaborated with notable colleagues, including Akwete L Adjei and Pramod K Gupta. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the field of pulmonary delivery.
Conclusion
Jack Zheng's contributions to the field of pulmonary delivery systems exemplify the impact of innovation in healthcare. His patent for formulations of dopamine agonists showcases his commitment to improving patient outcomes through advanced drug delivery methods.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
